These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2619876)

  • 1. MHC and antigen presentation.
    Askonas BA; Openshaw PJ
    Immunol Today; 1989 Dec; 10(12):396-7. PubMed ID: 2619876
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunology. The ins and outs of antigen processing and presentation.
    Germain RN
    Nature; 1986 Aug 21-27; 322(6081):687-9. PubMed ID: 3489186
    [No Abstract]   [Full Text] [Related]  

  • 3. The structure and function of MHC molecules. Possible implications for the control of tumor growth by MHC-restricted T cells.
    Kourilsky P; Jaulin C; Ley V
    Semin Cancer Biol; 1991 Oct; 2(5):275-82. PubMed ID: 1773044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturally-occurring peptide antigens derived from the MHC class-I-restricted processing pathway.
    Rötzschke O; Falk K
    Immunol Today; 1991 Dec; 12(12):447-55. PubMed ID: 1723878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The binary logic of antigen processing and presentation to T cells.
    Yewdell JW; Bennink JR
    Cell; 1990 Jul; 62(2):203-6. PubMed ID: 1695549
    [No Abstract]   [Full Text] [Related]  

  • 6. Trypanosoma cruzi infection does not impair major histocompatibility complex class I presentation of antigen to cytotoxic T lymphocytes.
    Buckner FS; Wipke BT; Van Voorhis WC
    Eur J Immunol; 1997 Oct; 27(10):2541-8. PubMed ID: 9368608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral antigen presentation and MHC assembly.
    Braciale TJ; Braciale VL
    Semin Immunol; 1992 Apr; 4(2):81-4. PubMed ID: 1617167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Processing of a minimal antigenic peptide alters its interaction with MHC molecules.
    Fox BS; Carbone FR; Germain RN; Paterson Y; Schwartz RH
    Nature; 1988 Feb; 331(6156):538-40. PubMed ID: 2448649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presentation of mouse tum- P91A antigen from chimeric proteins with different subcellular localizations by class I molecules of the major histocompatibility complex.
    Godelaine D; Van Pel A; Van Malderen M; Beaufay H
    Eur J Immunol; 1993 Jul; 23(7):1731-4. PubMed ID: 8325345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advances in the study of molecular mechanisms, applications and screening for altered peptide ligand].
    Wang QQ; Yang HZ; Hu ZW
    Yao Xue Xue Bao; 2008 Feb; 43(2):113-7. PubMed ID: 18507334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manifestation of the MHC-unrestricted killing potential of a cytotoxic T cell clone requires activation in response to MHC-restricted self-presentation of antigen.
    Dick T; Staege MS; Reichmann G; Reske-Kunz AB
    J Immunol; 1993 Apr; 150(7):2575-83. PubMed ID: 8454844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytosolic targeting of hen egg lysozyme gives rise to a short-lived protein presented by class I but not class II major histocompatibility complex molecules.
    Calin-Laurens V; Forquet F; Mottez E; Kanellopoulos J; Godeau F; Kourilsky P; Gerlier D; Rabourdin-Combe C
    Eur J Immunol; 1991 Mar; 21(3):761-9. PubMed ID: 2009914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
    Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
    Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indirect presentation of allogeneic major histocompatibility complex antigens by syngeneic macrophages.
    Dutta D; Meeusen E; Boyle W
    Transplant Proc; 1985 Apr; 17(2):1661-3. PubMed ID: 3157249
    [No Abstract]   [Full Text] [Related]  

  • 15. Specific epitope-induced conversion of CD8+ memory cells into effector cytotoxic T lymphocytes in vitro: presentation of peptide antigen by CD8+ T cells.
    Kos FJ; Müllbacher A
    Eur J Immunol; 1992 Jun; 22(6):1595-601. PubMed ID: 1376266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of MHC product induction may contribute to the immunosuppressive action of ciclosporin.
    Halloran PF; Wadgymar A; Autenried P
    Prog Allergy; 1986; 38():258-68. PubMed ID: 2425369
    [No Abstract]   [Full Text] [Related]  

  • 17. The seven rules of MHC restriction.
    Klein J; Marusić M; Nagy ZA
    Transplant Proc; 1982 Sep; 14(3):581-3. PubMed ID: 6184862
    [No Abstract]   [Full Text] [Related]  

  • 18. Fate of intercellular MHC-peptide-T-cell receptor complexes during T-cell activation.
    Clark BR
    J Mol Recognit; 1995; 8(1-2):63-6. PubMed ID: 7598954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic T lymphocytes, interleukin-2 and trophoblast involvement.
    Toder V; Blank M; Nebel L
    Contrib Gynecol Obstet; 1985; 14():23-35. PubMed ID: 2415297
    [No Abstract]   [Full Text] [Related]  

  • 20. [Molecular basis for detection of infectious agents].
    Siegrist CA
    Schweiz Med Wochenschr; 1996 Feb; 126(7):246-54. PubMed ID: 8720322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.